Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Xeris Biopharma Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A FAST-GROWING BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THE U.S PATENT AND TRADEMARK OFFICE HAS ISSUED PATENT NUMBER 12,377,096 TO THE COMPANY FOR RECORLEV (LEVOKETOCONAZOLE) AND THAT THIS PATENT IS NOW LISTED IN THE PUBLICATION, APPROVED DRUG PRODUCTS WITH THERAPEUTICS EQUIVALENCE EVALUATIONS, COMMON.

XERIS ANNOUNCES ORANGE BOOK LISTING OF U.S. PATENT FOR RECORLEV

CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A FAST-GROWING BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND UPDATED ITS FISCAL 2025 GUIDANCE. TOTAL REVENUE IN THE SECOND QUARTER INCREASED ALMOST 50% YEAR-OVER-YEAR TO A RECORD $72 MILLION, DRIVEN BY INCREASED PATIENT DEMAND ACROSS ALL THREE.

XERIS BIOPHARMA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND RAISES FULL YEAR REVENUE GUIDANCE

CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A FAST-GROWING BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE ITS SECOND QUARTER 2025 FINANCIAL RESULTS BEFORE THE OPEN OF THE U.S. FINANCIAL MARKETS ON THURSDAY, AUGUST 7, 2025. MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:30 A.M. EASTERN TIME THAT DAY TO DISCUSS THE C.

XERIS BIOPHARMA TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 7, 2025

CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A FAST-GROWING BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, WILL HOST ITS FIRST-EVER ANALYST AND INVESTOR DAY TODAY TO SHOWCASE ITS STRATEGY FOR SUSTAINABLE GROWTH AND VALUE CREATION. WE HAVE BUILT A STRONG FOUNDATION THROUGH INNOVATION AND A RELENTLESS COMMITMENT TO IMPROVING PATIENT LIVES. WE WILL SHOWCASE HOW THESE ACHI.

XERIS UNVEILS STRATEGY FOR LONG-TERM GROWTH AND VALUE CREATION AT 2025 ANALYST & INVESTOR DAY

CHICAGO--(BUSINESS WIRE)--XERIS ANNOUNCES DETAILS FOR ANALYST & INVESTOR DAY.

XERIS ANNOUNCES DETAILS FOR ANALYST & INVESTOR DAY

CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A FAST-GROWING BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND UPDATED ITS FISCAL 2025 TOTAL REVENUE GUIDANCE. WE'RE VERY PLEASED WITH OUR STRONG START TO THE YEAR, DELIVERING ANOTHER QUARTER OF OUTSTANDING REVENUE GROWTH, SAID JOHN SHANNON, XE.

XERIS BIOPHARMA REPORTS RECORD FIRST QUARTER 2025 FINANCIAL RESULTS

CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED CHANGES TO ITS BOARD OF DIRECTORS. RICKI FAIRLEY HAS RESIGNED FROM THE BOARD IN LIGHT OF OTHER COMMITMENTS, EFFECTIVE IMMEDIATELY. THE BOARD OF DIRECTORS HAS APPOINTED JAMES BRADY AS A NEW DIRECTOR OF XERIS' BOARD TO FILL THE VACANCY. IN ADDITION.

XERIS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT DR. ANH NGUYEN HAS JOINED XERIS AS CHIEF MEDICAL OFFICER (CMO) SUCCEEDING KEN JOHNSON PHARMD, SVP, GLOBAL DEVELOPMENT AND MEDICAL AFFAIRS WHO WILL RETIRE APRIL 1, 2025. DR. NGUYEN WILL DEVELOP AND LEAD THE ENTIRE PRODUCT PORTFOLIO VISION AND.

XERIS APPOINTS ANH NGUYEN, MD, MBA AS CHIEF MEDICAL OFFICER

STRATEGIC COLLABORATION FORMED TO RAISE AWARENESS THAT ALL PEOPLE WITH DIABETES ON BLOOD GLUCOSE-LOWERING MEDICATIONS SHOULD HAVE GLUCAGON, PREFERABLE A READY-TO-USE FORMULATION CHICAGO AND ARLINGTON, VA. , JAN. 21, 2025 /PRNEWSWIRE/ -- THE AMERICAN DIABETES ASSOCIATION (ADA) AND XERIS PHARMACEUTICALS (XERIS BIOPHARMA HOLDINGS, INC.), A NATIONAL SUPPORTER OF THE ADA, ARE PLEASED TO ANNOUNCE A MULTI-YEAR STRATEGIC PARTNERSHIP TO REINFORCE THE IMPORTANCE OF PRESCRIBING GLUCAGON, PREFERABLY READY-TO-USE, FOR ALL INDIVIDUALS WITH DIABETES WHO ARE TREATED WITH INSULIN AND/OR INSULIN SECRETAGOGUES OR THOSE AT HIGH RISK OF HYPOGLYCEMIA (LOW BLOOD GLUCOSE, ALSO CALLED LOW BLOOD SUGAR), IN LINE WITH THE ADA'S RECENTLY UPDATED STANDARDS OF CARE IN DIABETES2025 (STANDARDS OF CARE).1 "SEVERE HYPOGLYCEMIA IS LIFE-THREATENING, AND PEOPLE WITH DIABETES ON BLOOD GLUCOSE-LOWERING MEDICATION ARE AT RISK FOR HYPOGLYCEMIA.

THE AMERICAN DIABETES ASSOCIATION AND XERIS PHARMACEUTICALS ANNOUNCE NATIONAL COLLABORATION TO PROVIDE LIFE-SAVING HYPOGLYCEMIA EDUCATION AND AWARENESS

CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS) TODAY ANNOUNCED IT EXPECTS TO GENERATE TOTAL 2024 REVENUE OF $203 MILLION, WHICH WILL EXCEED PREVIOUSLY ANNOUNCED 2024 TOTAL REVENUE GUIDANCE OF $198 MILLION TO $202 MILLION. THE COMPANY ALSO ANTICIPATES ENDING 2024 WITH OVER $71 MILLION IN CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS, GENERATING POSITIVE CASH FLOW IN THE FOURTH QUARTER. WE ACHIEVED ANOTHER RECORD QUARTER OF EXCEPTIONAL TOTAL REVENUE GROWTH WITH REVE.

Xeris Biopharma Holdings, Inc.

XERS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Xeris Biopharma Holdings, Inc.

XERS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

XERS